Immunotherapy for Kidney Cancer — The New First-Line Standard

Most patients with kidney cancer are not eligible. Immunotherapy is used mainly for advanced or metastatic kidney cancer, and after surgery for a selected group at high risk of the cancer returning. Kidney cancer that is confined to the kidney and fully removed by surgery is usually followed by monitoring instead.

Beyond stage, three things decide it. The first is subtype: most published guidance applies to clear-cell renal cell carcinoma, the commonest form. Non-clear-cell subtypes have far less evidence behind them and are often discussed case by case, or in a clinical trial.

The second is your medical history. Active autoimmune disease, an organ transplant, or ongoing high-dose steroids can make immunotherapy unsuitable or higher-risk, because it works by loosening restraints on the immune system rather than targeting the tumour directly.

The third is something patients expect and do not find here. In several other cancers a biomarker score is the gatekeeper. Kidney cancer is different — decisions in advanced disease do not usually hinge on a PD-L1 score. In colorectal cancer, by contrast, immunotherapy applies almost entirely to one biomarker group, as Immunotherapy for Colorectal Cancer: Only If You Are MSI-High sets out.

Nothing on this page decides eligibility. That rests on the histology report, the stage, previous treatment and overall fitness, read together by a medical oncologist.

Because kidney cancer responds to immune treatment in a way it never responded to chemotherapy. Advanced kidney cancer was managed for more than a decade with oral targeted therapy alone. NCCN and ESMO now place immunotherapy-based combinations ahead of that, as the preferred first-line option in advanced clear-cell disease.

Kidney cancer has never been a chemotherapy disease. Standard cytotoxic chemotherapy has very little activity in renal cell carcinoma, which is why it has no routine first-line role, and why the search for something else went on so long here.

What came before was also immune treatment, of a much blunter kind. Before targeted drugs, advanced kidney cancer was treated with high-dose cytokine therapy: lasting benefit in a small number of patients, but severe toxicity and intensive monitoring to deliver it safely. It left routine use once oral targeted therapy arrived, which restricts the blood supply a tumour builds for itself. That became the first-line standard and held the position for years. It remains an important class of drug in kidney cancer today.

Checkpoint inhibitor immunotherapy works on a different principle again. Instead of starving the tumour, it releases the brakes the tumour applies to immune cells, so the body can act against it. In the trials that guideline bodies cite, immunotherapy-based combinations produced deeper and longer-lasting responses in advanced clear-cell kidney cancer than targeted therapy used alone, and the recommendations changed to match.

The practical consequence is easy to miss. Someone whose plan was written several years ago may have been started on a first-line treatment that current guidance would no longer choose first. That is worth raising, not assuming.

Usually in combination. First-line treatment for advanced clear-cell kidney cancer is normally two immunotherapy drugs given together, or one immunotherapy drug paired with an oral targeted drug. Immunotherapy on its own is used in narrower situations — most often after surgery in selected high-risk patients, or where a combination would not be tolerable.

Which of these is chosen depends on the risk group the case falls into, how quickly the disease is moving, other medical conditions, and which side-effect profile is workable for you. At CION it is a tumour-board decision, and it should be explained to you before the first cycle.

Most patients who benefit see the cancer shrink partially or stop growing, rather than disappear completely. A smaller group has a response that lasts well beyond the treatment period. Some patients progress despite treatment, which usually shows on the first assessment scan. Response is judged on imaging at set points, not on how you feel.

This page will not attach a percentage to your case, and you should be wary of any page that does. Response varies by risk group, subtype and which combination is used. Your oncologist can set expectations against dated, published guidance from bodies such as NCCN, ESMO or ASCO — a far more useful reference point than a general figure lifted from elsewhere.

Early scans can also mislead. A tumour can look slightly larger at the first assessment because immune cells have flooded into it, not because the cancer has grown. Oncologists call this pseudoprogression. It is uncommon but real, which is why one early scan rarely ends treatment on its own — a confirmation scan is usually done before any decision to stop.

Assessment imaging is scheduled after a defined number of cycles rather than on request. At CION, immunotherapy itself is given as day care at our centres, while response-assessment CT and PET-CT are coordinated at partner imaging centres.

By protocol, before every cycle. Creatinine and eGFR are checked ahead of each infusion, alongside urine protein, thyroid, liver function and blood counts. The schedule is fixed rather than symptom-driven, because the point is to catch a change before it becomes something you can feel.

• Baseline, before the first cycle — creatinine, eGFR, urine protein, thyroid, liver and blood counts are recorded as the reference every later result is compared against. Without a baseline, one later number means very little.
• Before every cycle after that — the same panel is repeated. A rising creatinine is a trigger for review by the treating team, not automatically a reason to stop treatment.
• Closer review after a kidney has been removed — with one working kidney, dehydration, contrast dye and some over-the-counter painkillers carry more weight. Fluid intake and which painkillers are safe are agreed with the team, not assumed.
• Immune-related nephritis is a recognised, uncommon side effect — inflammation of the kidney can occur on checkpoint inhibitor treatment. Routine bloods usually pick it up before symptoms appear, and the oncology team manages it, commonly with steroids.
• What to report between cycles — a clear drop in how much urine you are passing, new swelling in the ankles or legs, or feeling unusually drowsy and unwell. Tell the treating team rather than waiting for the next appointment.

• In colorectal cancer, a single biomarker decides almost everything — Immunotherapy for Colorectal Cancer: Only If You Are MSI-High explains why most patients are ruled out on one test result.
• Breast cancer sits at the opposite end from kidney cancer, with a much narrower window — Immunotherapy for Breast Cancer: Who Is Actually Eligible covers who that window is open for.
• The one breast-cancer subtype with a defined role for immunotherapy is covered separately in Immunotherapy for Triple-Negative Breast Cancer.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Still unsure how any of this applies to a specific kidney cancer diagnosis? Book a free consultation and a medical oncologist will go through the reports with you.